Voronoi

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi Inc. to secure exclusive global development and commercialization rights to Voronoi’s pan-RAF inhibitor program. The deal involves an upfront payment of $1.7 million and up to $480.5 million in development, regulatory, and sales milestones, as…